NEW YORK, April 28, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), relating to the proposed merger with Merck KGaA, Darmstadt, Germany. Under the terms of the agreement, SpringWorks shareholders will h ...

NEW YORK, April 28, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) and its board of directors concerning the proposed acquisition of the company by Merck KGaA. Stockholders will receive $47.00 for each share of SpringWorks Therapeutics stock that they hold. The transaction is valued at approximately $3.4 billion and is expected to close in the second half of 2025.If you are a stockholder of SpringWorks Therapeutics, ...

– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business – – SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and c ...

Core Viewpoint - SpringWorks Therapeutics, Inc. anticipates a favorable opinion from the CHMP of the EMA regarding the marketing authorization application for nirogacestat in Q2 2025, aimed at treating adults with desmoid tumors [1] Company Overview - SpringWorks Therapeutics is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, with FDA-approved products including OGSIVEO (nirogacestat) for desmoid tumors and GOMEKLI™ (mirdametinib) for neurofibromatosis type 1 associated plexiform neurofibromas [2]

SpringWorks Therapeutics (SWTX) shares rallied 9% in the last trading session to close at $44.93. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.3% loss over the past four weeks.The sudden price rise can be attributed to growing investors’ optimism related to the company’s progress with its lead marketed product, Ogsiveo (nirogacestat), which is approved for treating Desmoid tumors. The drug has witnessed ...

SpringWorks Therapeutics (SWTX) incurred a loss of $1.04 per share in the fourth quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 72 cents. The company had reported a loss of $1.44 per share in the year-ago quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.In the fourth quarter, total revenues were $61.5 million, which beat the Zacks Consensus Estimate of $60 million. Total revenues comprised net product sales of Ogsiveo (nirogacestat). The company ge ...

YANCOAL AUSTRALIA LTD | ADDRESS: | Level 18, Tower 2, 201 Sussex Street, | | --- | --- | | | Sydney NSW 2000 | | PHONE: | 61 2 8583 5300 | | FAX: | 61 2 8583 5399 | | WEBSITE: | www.yancoal.com.au | 20 February 2025 ASX Release: 2024 Financial Results Presentation Authorised for lodgement by the Board of Yancoal Australia Investor Relations Contact: Brendan Fitzpatrick, GM Investor Relations Email: Brendan.Fitzpatrick@yancoal.com.au Additional information about the company can be found at www.yancoal.com.au ...

SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.44 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -44.44%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.76 per share when it actually produced a loss of $0.72, delivering a surprise of 5.26%.Over the last four quarter ...

Financial Performance - OGSIVEO generated net sales of $172.0 million in 2024, up from $5.4 million in 2023[549]. - The company recorded net product revenue of $172.0 million for the year ended December 31, 2024, compared to $5.4 million for the year ended December 31, 2023, reflecting a significant increase of $166.6 million[593]. - Total revenue for 2024 was $191,589 thousand, compared to $5,447 thousand in 2023, indicating a substantial growth[661]. - The net loss for 2024 was $258,131 thousand, an improvement from a net loss of $325,104 thousand in 2023[661]. - The company reported a net loss of $258.1 million for the year ended December 31, 2024, an improvement from a net loss of $325.1 million in 2023, and $277.4 million in 2022[671]. Cash and Securities - The company had cash, cash equivalents, and marketable securities of $461.9 million as of December 31, 2024, down from $662.6 million in 2023[558]. - Cash used in operating activities was $175.6 million in 2024, down from $222.8 million in 2023, indicating improved cash flow management[621]. - The company had cash, cash equivalents, and marketable securities totaling $461.9 million, down from $662.6 million as of December 31, 2023[680]. - The company’s accumulated deficit reached $1.2 billion as of December 31, 2024, compared to $895.0 million as of December 31, 2023[679]. - The company had no outstanding debt as of December 31, 2024[643]. Operating Expenses - Total operating expenses increased to $469.7 million for the year ended December 31, 2024, up from $348.5 million in 2023, representing a 35% increase[593]. - Research and development expenses rose to $200.5 million in 2024, an increase of $50.0 million or 33% compared to $150.5 million in 2023[593]. - Selling, general and administrative expenses were $256.7 million for the year ended December 31, 2024, a 30% increase from $197.6 million in 2023[593]. - The total equity-based compensation expense for 2024 was $109,140,000, compared to $94,534,000 in 2023, indicating a year-over-year increase of approximately 15.4%[737]. Regulatory Approvals and Product Development - GOMEKLI was approved by the FDA on February 11, 2025, for treating NF1-PN, with commercialization starting in the same month[550]. - The FDA approved OGSIVEO in November 2023, leading to revenue generation from sales starting in December 2023[578]. - The company anticipates ongoing regulatory reviews for nirogacestat and mirdametinib, with decisions expected in 2025[551]. - The company began capitalizing inventory for OGSIVEO upon its FDA approval in November 2023[692]. Collaborations and Agreements - The company has entered into a license agreement with Rappta Therapeutics for a portfolio of PP2A activators, with an upfront payment of $13 million and potential future milestones totaling up to $235 million[565]. - The company terminated its collaboration agreement with GSK, effective December 3, 2024, but will continue to support ongoing clinical trials[552]. - The company entered into several clinical trial collaboration agreements to evaluate nirogacestat in combination with BCMA-directed therapies[571]. Future Outlook - The company expects to continue incurring significant expenses related to the commercialization of OGSIVEO and GOMEKLI, as well as ongoing clinical development[560]. - The company anticipates achieving profitability in the first half of 2026, indicating a long-term outlook for financial recovery[614]. - The company expects research and development expenses to continue increasing as it invests in product candidates and preclinical programs[583]. Assets and Liabilities - Total assets decreased to $587,276 thousand in 2024 from $725,788 thousand in 2023, indicating a reduction in overall financial resources[659]. - The company's total accrued expenses increased to $86,012,000 in 2024, up from $65,569,000 in 2023, reflecting a significant rise in accrued compensation and benefits[736]. - The company's property and equipment, net, rose to $19,680,000 in 2024 from $17,943,000 in 2023, showing an increase of about 9.7%[731]. Stock Options and Compensation - The company had 12,818,963 stock options outstanding, with a weighted average exercise price of $35.90 and an intrinsic aggregate value of $105,568,481[742]. - The total unrecognized compensation expense related to unvested stock options was $100.2 million, expected to be recognized over approximately 2.2 years[743]. - The total restricted stock awards compensation expense for the year ended December 31, 2024, was $2.2 million, with 11,101 unvested shares outstanding at year-end[744].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 SPRINGWORKS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | Delaware | 001-39044 | 83-4066827 | | --- | --- | --- | | (State or other jurisdiction | (Commission | (IRS Employer | | of incorporation) | File Number) | Identification No.) | 100 Washingt ...